Hep-Art has developed a robust bio-artificial liver system, the AMC-BAL, to support end stage liver failure (ESLF) patients like acute liver failure (ALF) and acute on chronic liver failure (ACLF) to liver recovery or to the moment of donor-liver availability. The AMC-BAL is an extracorporeal supportive device that treats the plasma of the patients and temporarily replaces liver functions. The core of the system is a bioreactor that is loaded with the HepaRG human liver cell line. The power of the current HepaRG-based AMC-BAL system is advocated by a study in rats with ALF showing substantial increased survival time. We are currently preparing a first clinical trial with the HepaRG-AMC-BAL in patients with ACLF.
|Meibergdreef 45, 1105 BA, Amsterdam
|Company phone, e-mail & contact person
|email@example.com – Robert Chamuleau
|URL Company website